Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Revenue of Biogen Inc. (BIIB)
Revenue in 2023 (TTM): $9.84 B
According to Biogen Inc.'s latest financial reports the company's current revenue (TTM) is $9.84 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Biogen Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $9.84 B | $7.3 B | $2.38 B | $1.3 B | $1.16 B |
| 2022 | $10.17 B | $7.9 B | $4.36 B | $3.59 B | $3.05 B |
| 2021 | $10.98 B | $8.87 B | $2.49 B | $1.75 B | $1.56 B |
| 2020 | $13.44 B | $11.64 B | $5.73 B | $5.05 B | $4 B |
| 2019 | $14.38 B | $12.42 B | $7.78 B | $7.13 B | $5.89 B |
| 2018 | $13.45 B | $11.64 B | $6.75 B | $5.9 B | $4.43 B |
| 2017 | $12.27 B | $10.64 B | $6.1 B | $5.13 B | $2.54 B |
| 2016 | $11.45 B | $9.97 B | $5.88 B | $4.93 B | $3.7 B |
| 2015 | $10.76 B | $9.52 B | $5.62 B | $4.77 B | $3.55 B |
| 2014 | $9.7 B | $8.53 B | $4.66 B | $3.95 B | $2.93 B |
| 2013 | $6.93 B | $6.07 B | $3.02 B | $2.48 B | $1.86 B |
| 2012 | $5.52 B | $4.97 B | $2.26 B | $1.86 B | $1.38 B |
| 2011 | $5.05 B | $4.58 B | $2.1 B | $1.71 B | $1.23 B |
| 2010 | $4.72 B | $4.32 B | $1.62 B | $1.23 B | $1.01 B |
| 2009 | $4.38 B | $4 B | $1.8 B | $1.33 B | $970.13 M |
| 2008 | $4.1 B | $3.7 B | $1.67 B | $1.15 B | $783.17 M |
| 2007 | $3.17 B | $2.84 B | $1.27 B | $910.6 M | $638.17 M |
| 2006 | $1.87 B | $1.6 B | $875.67 M | $492.16 M | $217.51 M |
| 2005 | $1.71 B | $1.34 B | $668.05 M | $256.2 M | $160.71 M |
| 2004 | $1.6 B | $1.04 B | $522.43 M | $64.09 M | $25.09 M |
| 2003 | $679.18 M | $394.44 M | $-804,134,000 | $-880,624,000 | $-875,097,000 |
| 2002 | $1.15 B | $988.21 M | $257.75 M | $276.6 M | $199.15 M |
| 2001 | $1.04 B | $906.85 M | $367.81 M | $389.5 M | $272.68 M |
| 2000 | $926.45 M | $801.25 M | $208.43 M | $487.11 M | $333.58 M |
| 1999 | $794.44 M | $683.43 M | $347.35 M | $329.02 M | $220.45 M |
| 1998 | $557.59 M | $483.08 M | $215.23 M | $210.19 M | $138.7 M |
| 1997 | $434.04 M | $383.86 M | $168.26 M | $148.97 M | $89.17 M |
| 1996 | $277.09 M | $248.57 M | $56.09 M | $40.83 M | $40.53 M |
| 1995 | $151.69 M | $141.19 M | $18.36 M | $7.45 M | $5.66 M |
| 1994 | $156.34 M | $146.4 M | $6.15 M | $-1,907,000 | $-4,897,000 |
| 1993 | $136.4 M | $130.9 M | $15.5 M | $34.6 M | $32.4 M |
| 1992 | $123.7 M | $121.5 M | $24.3 M | $39.9 M | $38.3 M |
| 1991 | $61.4 M | $18.1 M | $-4,900,000 | $7.5 M | $7.2 M |
| 1990 | $50.1 M | $14.7 M | $-2,600,000 | $8 M | $7.7 M |
| 1989 | $28.5 M | $3.3 M | $-18,100,000 | $3.4 M | $3.2 M |
| 1988 | $20.6 M | $-500,000 | $-8,800,000 | $-900,000 | $-1,200,000 |
| 1987 | $8.6 M | $-12,400,000 | $-20,400,000 | $-22,400,000 | $-22,600,000 |
| 1986 | $6.4 M | $-16,900,000 | $-25,000,000 | $-27,800,000 | $-28,200,000 |
| 1985 | $15.1 M | $10.6 M | $-28,400,000 | $-18,700,000 | $-19,100,000 |